Higher Costs, Higher Fees, Higher Drug Prices: The UK No-Deal Brexit Bonus

A freestanding UK Medicines and Healthcare products Regulatory Agency with a dedicated authorization route for new drugs OKd by the European Medicines Agency and national incentives for pediatric and orphan drug development are just some of the likely outcomes of a no-deal Brexit as described in a consultation document just released by the government. In many cases companies will end up paying again for services they currently receive from the EMA, and, the government says, they may pass these extra costs onto the national health service in the form of higher prices.

The UK will set up its own drug approval procedures in the event of a no-deal Brexit